Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2016

View Archived Issues

BioLineRx and Genentech to investigate atezolizumab plus BL-8040 in oncology indications

Idera finds unique mechanism behind third-generation antisense oligonucleotides

First clinical data reported for asthma candidate BI-1060469

AZD-8999 shows good bronchodilator profile in phase I trial in patients with COPD

Moerae Matrix presents phase I data for MMI-0100

Glenmark announces discovery of GBR-1372

Emmaus submits NDA for sickle cell disease treatment

DelMar Pharmaceuticals and Accurexa to develop combination chemotherapy for brain cancer

FDA expands EUA for Aptima Zika virus diagnostic assay to be used with urine samples

LentiGlobin enters phase III testing in patients with transfusion-dependent beta-thalassemia

FDA clears clinical testing of Carmeseal-MD in DMD

GTx's phase II study of enobarsarm achieves stage one milestone

Alnylam Pharmaceuticals provides interim phase I data for ALN-AS1 in acute intermittent porphyria

Celyad completes phase I trial of NKR-2 T-cell therapy

Data on long-term administration of rhGUS in mucopolysaccharidosis type VII reported

Stanford University and twoXAR enter HCC collaboration

RedHill Biopharma begins phase Ib/II study of Yeliva

Cytokinetics reaches milestone in skeletal muscle activator collaboration with Astellas

Oncoceutics provides update on phase I study of ONC-201

Screening study set to open for irofulven trial in prostate cancer

Axxam and Mercachem announce strategic alliance

HDAC/PI3K inhibitor from Curis granted orphan drug status in the U.S.

Bristol-Myers Squibb, Universite de Montreal patent novel PAR4 antagonists

NIH announces launch of ADNI3

University of Michigan discloses new bromodomain-containing protein 4 inhibitors

Nimbus Lakshmi presents novel TYK2 inhibitors

Lycera presents novel Rho-associated protein kinase 2 inhibitors

Curtana Pharmaceuticals describes new Oligo2 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...